Opinion|Videos|May 30, 2024
Efficacy Outcomes: Progression-Free Survival, Response Rates, and Duration of Response in MARIPOSA-2
This segment focuses on the key efficacy data on progression-free survival, response rates, and duration of response from MARIPOSA-2.
Advertisement
Episodes in this series
Advertisement
Related to this article
Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.
Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.
Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoadjuvant Radiation May Improve Tolerability in Cholangiocarcinoma
2
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
3
Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy
4
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
5